{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:29:47Z","timestamp":1790634587987,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570270"],"award-info":[{"award-number":["81570270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570276"],"award-info":[{"award-number":["81570276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-015"],"award-info":[{"award-number":["2016-I2M-1-015"]}]},{"name":"Innovation Foundation for Students of Peking Union Medical College","award":["2015-1002-02-19"],"award-info":[{"award-number":["2015-1002-02-19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Animal studies suggested that blocking the activation of the mammalian target of rapamycin (mTOR) pathway might be effective to treat cardiac hypertrophy in LEOPARD syndrome (LS) caused by\n                      <jats:italic>PTPN11<\/jats:italic>\n                      mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the present study, mTOR pathway activity was examined in human myocardial samples from two patients with LS, four patients with hypertrophic cardiomyopathy (HCM), and four normal controls. The two patients with LS had p.Y279C and p.T468\u2009M mutations of the\n                      <jats:italic>PTPN11<\/jats:italic>\n                      gene, respectively. Although\n                      <jats:italic>PTPN11<\/jats:italic>\n                      mutation showed initially positive regulation on phosphoinositide 3-kinase, overall the mTOR complex 1 pathway showed widely attenuated activity in LS. This included mildly hypophosphorylated mTOR and ribosomal protein S6 kinase and significantly hypophosphorylated Akt\n                      <jats:sup>308<\/jats:sup>\n                      and ribosomal protein S6, which is similar to HCM. Akt\n                      <jats:sup>473<\/jats:sup>\n                      is a basal molecule of the mTOR complex 2 pathway. Akt\n                      <jats:sup>473<\/jats:sup>\n                      was less affected and showed hyperactivity in LS compared with HCM and normal controls. Additionally, MAPK\/ERK kinase and ERK1\/2 were significantly more phosphorylated in both HCM and LS than normal controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In LS, the mTOR signaling pathway shows similar activity to HCM and is attenuated compared with normal controls. Thus, caution should be applied when using rapamycin to treat heart hypertrophy in LS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-019-1204-4","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T13:02:39Z","timestamp":1573650159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?"],"prefix":"10.1186","volume":"14","author":[{"given":"Hao","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutai","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"1204_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1750-1172-3-13","volume":"3","author":"A Sarkozy","year":"2008","unstructured":"Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13.","journal-title":"Orphanet J Rare Dis"},{"key":"1204_CR2","volume-title":"GeneReviews\u00ae","author":"BD Gelb","year":"2007","unstructured":"Gelb BD, Tartaglia M. Noonan Syndrome with Multiple Lentigines. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews\u00ae. Seattle: University of Washington, Seattle; 2007."},{"key":"1204_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-019-1010-z","volume":"14","author":"H Chen","year":"2019","unstructured":"Chen H, Li X, Liu X, et al. Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort. Orphanet J Rare Dis. 2019;14:29.","journal-title":"Orphanet J Rare Dis"},{"key":"1204_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-019-1151-0","volume":"14","author":"G Calcagni","year":"2019","unstructured":"Calcagni G, Digilio MC, Marino B, Tartaglia M. Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations. Orphanet J Rare Dis. 2019;14:163.","journal-title":"Orphanet J Rare Dis"},{"key":"1204_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1172\/JCI44972","volume":"121","author":"TM Marin","year":"2011","unstructured":"Marin TM, Keith K, Davies B, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121:1026\u201343.","journal-title":"J Clin Invest"},{"key":"1204_CR6","doi-asserted-by":"publisher","first-page":"H231","DOI":"10.1152\/ajpheart.00665.2011","volume":"302","author":"C Schramm","year":"2012","unstructured":"Schramm C, Fine DM, Edwards MA, Reeb AN, Krenz M. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. Am J Physiol Heart Circ Physiol. 2012;302:H231\u201343.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1204_CR7","doi-asserted-by":"publisher","first-page":"18335","DOI":"10.1074\/jbc.M113.483800","volume":"288","author":"C Schramm","year":"2013","unstructured":"Schramm C, Edwards MA, Krenz M. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling. J Biol Chem. 2013;288:18335\u201344.","journal-title":"J Biol Chem"},{"key":"1204_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ajmg.a.36982","volume":"167A","author":"A Hahn","year":"2015","unstructured":"Hahn A, Lauriol J, Thul J, et al. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. Am J Med Genet A. 2015;167A:744\u201351.","journal-title":"Am J Med Genet A"},{"key":"1204_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","volume":"58","author":"M Tajan","year":"2015","unstructured":"Tajan M, de Rocca SA, Valet P, Edouard T, Yart A. SHP2 sails from physiology to pathology. Eur J Med Genet. 2015;58:509\u201325.","journal-title":"Eur J Med Genet"},{"key":"1204_CR10","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.M513068200","volume":"281","author":"MI Kontaridis","year":"2006","unstructured":"Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem. 2006;281:6785\u201392.","journal-title":"J Biol Chem"},{"key":"1204_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.semcdb.2014.09.013","volume":"37","author":"J Lauriol","year":"2015","unstructured":"Lauriol J, Jaffr\u00e9 F, Kontaridis MI. The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease. Semin Cell Dev Biol. 2015;37:73\u201381.","journal-title":"Semin Cell Dev Biol"},{"key":"1204_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/jhg.2015.114","volume":"61","author":"Y Aoki","year":"2016","unstructured":"Aoki Y, Niihori T, Inoue S-I, Matsubara Y. Recent advances in RASopathies. J Hum Genet. 2016;61:33\u20139.","journal-title":"J Hum Genet"},{"key":"1204_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrm3757","volume":"15","author":"M Shimobayashi","year":"2014","unstructured":"Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15:155\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1204_CR14","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/01.tp.0000542599.31551.98","volume":"102","author":"E Paoletti","year":"2018","unstructured":"Paoletti E. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy. Transplantation. 2018;102:S41\u20133.","journal-title":"Transplantation"},{"key":"1204_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.110.977066","volume":"123","author":"P Shende","year":"2011","unstructured":"Shende P, Plaisance I, Morandi C, et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011;123:1073\u201382.","journal-title":"Circulation"},{"key":"1204_CR16","volume-title":"GeneReviews(R)","author":"JE Allanson","year":"1993","unstructured":"Allanson JE, Roberts AE. Noonan Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews(R). Seattle: University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993."},{"key":"1204_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/ng2073","volume":"39","author":"B Pandit","year":"2007","unstructured":"Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007\u201312.","journal-title":"Nat Genet"},{"key":"1204_CR18","volume-title":"GeneReviews(R)","author":"BD Gelb","year":"1993","unstructured":"Gelb BD, Tartaglia M. Noonan Syndrome with Multiple Lentigines. In: Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews(R). Seattle: University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., 1993."},{"key":"1204_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2459\/JCM.0b013e32834a658f","volume":"12","author":"G Mercuro","year":"2011","unstructured":"Mercuro G, Bassareo PP, Deidda M, Cadeddu C, Barberini L, Atzori L. Metabolomics: a new era in cardiology? J Cardiovasc Med. 2011;12:800\u20135.","journal-title":"J Cardiovasc Med"},{"key":"1204_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ejhf.144","volume":"16","author":"J Wang","year":"2014","unstructured":"Wang J, Wang Y, Zou Y, et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail. 2014;16:950\u20137.","journal-title":"Eur J Heart Fail"},{"key":"1204_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.tcm.2012.03.006","volume":"21","author":"J Lauriol","year":"2011","unstructured":"Lauriol J, Kontaridis MI. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med. 2011;21:97\u2013104.","journal-title":"Trends Cardiovasc Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1204-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1204-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1204-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T19:07:38Z","timestamp":1605121658000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1204-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1204-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"28 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Fuwai Hospital (Beijing, China). It was performed under the ethical principles stated by the Declaration of Helsinki. All participants provided informed consent and permission for using their biological samples.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided informed consent and permission for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}